Medical device CRO Factory brings Boston Biomedical into its fold

Handshake business deal executives
Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates. (Pixabay)

Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates.

Financial terms of the deal weren’t announced.

With the addition of Boston Biomedical, Factory-CRO Group now boasts expanded operations in the U.S., as well as sites in Australia, New Zealand and Europe. Factory-CRO Group said its goal is to become the leading global CRO focused on medical devices and medical technology. 


Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

“This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience,” Dirk Meijer, M.D., Ph.D., the company’s chief executive, said in a statement. “We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”

A little over a year ago, Factory-CRO Group acquired Milestone Research Organization. Factory-CRO Group offers medical device companies services in data management, consultancy regarding study design and budget and regulatory strategy, regulatory filings, clinical monitoring and reimbursement.

Suggested Articles

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.

WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.